BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 38481726)

  • 1. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
    Zisis K; Pavi E; Geitona M; Athanasakis K
    J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
    Capkun G; Corry S; Dowling O; Asad Zadeh Vosta Kolaei F; Takyar S; Furtado C; Jónsson P; Kleinermans D; Lambert L; Schiel A; Facey K
    Int J Technol Assess Health Care; 2022 Nov; 38(1):e79. PubMed ID: 36321447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of real-world evidence from different data sources in health technology assessment.
    Graili P; Guertin JR; Chan KKW; Tadrous M
    J Pharm Pharm Sci; 2023; 26():11460. PubMed ID: 37529633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
    Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
    Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to Deal with the Inevitable: Generating Real-World Data and Using Real-World Evidence for HTA Purposes - From Theory to Action.
    Oortwijn W; Sampietro-Colom L; Trowman R
    Int J Technol Assess Health Care; 2019; 35(4):346-350. PubMed ID: 31198129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
    Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL
    Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
    Facey KM; Rannanheimo P; Batchelor L; Borchardt M; de Cock J
    Int J Technol Assess Health Care; 2020 Sep; ():1-10. PubMed ID: 32878663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal.
    Pongiglione B; Torbica A; Blommestein H; de Groot S; Ciani O; Walker S; Dams F; Blankart R; Mollenkamp M; Kovács S; Tarricone R; Drummond M
    Int J Technol Assess Health Care; 2021 Apr; 37(1):e62. PubMed ID: 33896433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.
    Claire R; Elvidge J; Hanif S; Goovaerts H; Rijnbeek PR; Jónsson P; Facey K; Dawoud D
    Front Pharmacol; 2023; 14():1289365. PubMed ID: 38283835
    [No Abstract]   [Full Text] [Related]  

  • 13. Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps.
    Gomes M; Turner AJ; Sammon C; Dawoud D; Ramagopalan S; Simpson A; Siebert U
    Value Health; 2024 May; 27(5):623-632. PubMed ID: 38369282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transferability of real-world data across borders for regulatory and health technology assessment decision-making.
    Jaksa A; Arena PJ; Chan KKW; Ben-Joseph RH; Jónsson P; Campbell UB
    Front Med (Lausanne); 2022; 9():1073678. PubMed ID: 36465931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
    Sola-Morales O; Curtis LH; Heidt J; Walsh L; Casso D; Oliveria S; Saunders-Hastings P; Song Y; Mercado T; Zusterzeel R; Mastey V; Harnett J; Quek RGW
    Clin Pharmacol Ther; 2023 Aug; 114(2):325-355. PubMed ID: 37079433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
    Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.